密苏里州,堪萨斯州和爱达荷州起诉FDA,因为未经批准的基因药物米费普里斯顿,并称其安全性和监督问题. Missouri, Kansas, and Idaho sue FDA over generic mifepristone approval, citing safety and oversight concerns.

密苏里州总检察长凯瑟琳·汉纳威 (Catherine Hanaway) 起诉FDA批准一款通用版本的米费普里斯药物, 认为这会给安全带来风险, 破坏监管, 特别是因为该药物可以在网上订购并通过邮件送达. Missouri Attorney General Catherine Hanaway has sued the FDA over its approval of a generic version of mifepristone, arguing it poses safety risks and undermines regulatory oversight, particularly as the drug can be ordered online and delivered by mail. 该诉讼案由堪萨斯州和爱达荷州加入,是限制获得堕胎药物的更广泛努力的一部分。 The lawsuit, joined by Kansas and Idaho, is part of broader efforts to restrict access to abortion medications. FDA基于科学证据坚持认为仿制药是安全有效的。 The FDA maintains the generic version is safe and effective based on scientific evidence. 在2024年通过保护堕胎权利的《第三修正案》后,密苏里的堕胎情况仍然有争议,尽管2026年的投票措施试图限制在强奸、乱伦或医疗紧急情况下进行早期堕胎的机会。 Missouri’s abortion landscape remains contested following the 2024 passage of Amendment Three, which protects abortion rights, though a 2026 ballot measure seeks to limit access to early-term abortions in cases of rape, incest, or medical emergencies. 法律挑战可能会影响联邦毒品管制和全国的生殖权利。 The legal challenge could influence federal drug regulation and reproductive rights nationwide.